218 related articles for article (PubMed ID: 33360170)
1. Ocular myasthenia gravis - How effective is low dose prednisone long term?
Verma R; Wolfe GI; Kupersmith MJ
J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
[TBL] [Abstract][Full Text] [Related]
2. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
Kupersmith MJ
J Neurol; 2009 Aug; 256(8):1314-20. PubMed ID: 19377863
[TBL] [Abstract][Full Text] [Related]
3. Response to treatment in pediatric ocular myasthenia gravis.
Xu L; Castro D; Reisch JS; Iannaccone ST
Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
[TBL] [Abstract][Full Text] [Related]
4. Childhood myasthenia gravis: clinical features and outcomes.
Sri-udomkajorn S; Panichai P; Liumsuwan S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
[TBL] [Abstract][Full Text] [Related]
5. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
[TBL] [Abstract][Full Text] [Related]
6. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
7. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
[TBL] [Abstract][Full Text] [Related]
8. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Kupersmith MJ; Ying G
Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
[TBL] [Abstract][Full Text] [Related]
9. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
[TBL] [Abstract][Full Text] [Related]
10. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Allen JA; Scala S; Jones HR
Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
[TBL] [Abstract][Full Text] [Related]
11. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
12. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.
Feng X; Huan X; Yan C; Song J; Lu J; Zhou L; Wu H; Qiao K; Lu J; Xi J; Luo S; Zhao C
Eur Neurol; 2020; 83(2):182-188. PubMed ID: 32526733
[TBL] [Abstract][Full Text] [Related]
13. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Bi Z; Cao Y; Gui M; Lin J; Zhang Q; Li Y; Ji S; Bu B
Neurol Sci; 2023 Apr; 44(4):1383-1391. PubMed ID: 36469201
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
[TBL] [Abstract][Full Text] [Related]
15. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
16. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.
Bi Z; Ge H; Zhang Q; Gao H; Yang M; Zhan J; Lin J; Gui M; Li Y; Ji S; Cao Y; Bu B
Pediatr Neurol; 2023 Sep; 146():31-39. PubMed ID: 37421800
[TBL] [Abstract][Full Text] [Related]
17. Low conversion rate of ocular to generalized myasthenia gravis in Singapore.
Teo KY; Tow SL; Haaland B; Gosavi TD; Jing-Liang L; Yew Long LO; Milea D
Muscle Nerve; 2018 May; 57(5):756-760. PubMed ID: 28981152
[TBL] [Abstract][Full Text] [Related]
18. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study.
Hendricks TM; Bhatti MT; Hodge DO; Chen JJ
Am J Ophthalmol; 2019 Sep; 205():99-105. PubMed ID: 31077669
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
Isshiki Y; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
[TBL] [Abstract][Full Text] [Related]
20. Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China.
Ding J; Zhao S; Ren K; Dang D; Li H; Wu F; Zhang M; Li Z; Guo J
BMC Neurol; 2020 Jun; 20(1):238. PubMed ID: 32527235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]